Eli Lilly Will Trade at This Price in a Year

Quick Read

• Retatrutide’s 19% weight loss data pushed LLY to a 52-week high, and four straight EPS beats make the $1,500 optimistic target achievable.

  Contents

  Quick Read What’s Holding Eli Lilly Back in 2026 Wall Street Sees 6% Upside. That’s Too Cautious The Path to $1,500 Per Share Where Lilly Trades Today vs Its Earnings Power Is $1,500 Realistic?

• AZN’s elecoglipron delivered only 12% weight loss in Phase 3 versus retatrutide’s 19%, leaving Lilly well ahead in the race for GLP-1 dominance.

• TD Cowen projects LLY captures 62% of the $150 billion 2030 GLP-1 market, with four directors buying shares near $950 this spring.

• Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today.

Eli Lilly (NYSE:LLY) is finally acting like a trillion-dollar drugmaker again. After a brutal stretch in late 2025 and a wobbly start to this year, the stock punched through fresh 52-week highs on retatrutide Phase 3 data that analysts call potentially first-line for obesity. The stock trades at $1,149.15 with a one-year gain of 50.31%, yet YTD is only 7.29%. Can LLY hit $1,500 within 12 months?

What’s Holding Eli Lilly Back in 2026

Shares rose 21.37% in the last month and 6.19% in the last week, but YTD trails the one-year number because investors spent Q1 worrying about China NRDL pricing pressure, $584M in IPR&D charges from four acquisitions, and 340B restrictions.

AstraZeneca (NASDAQ:AZN)’s elecoglipron entering Phase 3 added competitive pressure, though it showed only 11.8% weight loss versus retatrutide’s roughly 19%. Beta is a placid 0.517, so earlier volatility reflected earnings noise rather than broad market moves. That explains why patient capital is pushing the stock back toward $1,500.

Wall Street Sees 6% Upside. That’s Too Cautious

Consensus target is $1,215.10, with 6 Strong Buys, 18 Buys, 5 Holds, 1 Sell and 1 Strong Sell. That works out to 77% bullish, yet implied upside is only single digits. Our base case sits at $1,295.73 (12.76% upside) with 90% confidence, optimistic case $1,499.61, conservative $1,074.25. Analysts have chased this stock for four straight quarters of earnings beats.

Q1 2026 EPS of $8.55 versus $6.79 estimated was a 25.9% surprise. Earnings growth drove meaningful tailwind in our 247Factor, and bullishness keeps building. Targets are stale.

The Path to $1,500 Per Share

Reaching $1,500 from $1,149.15 requires a 30.5% gain. With forward EPS of $35.46, $1,500 implies a forward P/E of 42x. Our base case embeds an implied multiple of 39x, so the target needs only about 3 turns of additional multiple expansion. That is achievable.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today.

Catalysts already in play: Reuters reported “Eli Lilly’s shares rose 4% after presenting compelling new data for its next-generation obesity drug, retatrutide”; TD Cowen projects LLY captures roughly 62% of the $150 billion 2030 GLP-1 market; and CEO David Ricks said “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion”.

Four directors also bought stock in March, April, and May 2026 at prices between $919.90 and $989.12. The primary risk is a Supreme Court ruling or aggressive Medicare pricing action that compresses GLP-1 margins.

Where Lilly Trades Today vs Its Earnings Power

At $1,149.15 against forward EPS of $35.46, LLY trades at a forward P/E of 32x. For a company growing revenue 55.5% YoY with raised FY2026 guidance of $82B to $85B in revenue and $35.5 to $37 in non-GAAP EPS, that is reasonable.

Shares sit at the 52-week high of $1,166.29, well above the 52-week low of $619.40. The 10-year return of 1,725.98% shows what compounding earnings power looks like when the pipeline works.

Is $1,500 Realistic?

A 30.5% gain in a year is a stretch for a mega-cap with a 0.52 beta, but not a long shot.

Three things need to happen: retatrutide must keep impressing through regulatory filings; Foundayo, the new oral GLP-1, needs real script momentum after the CVS Caremark coverage expansion; and Lilly needs another guidance raise into Q3 2026. A reset of GLP-1 reimbursement would derail it. We’ve outlined the blueprint for how Eli Lilly could reach $1,500 in 2027.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today.